Summary of Key Points Core Viewpoint - NuoVaxan's stock performance and financing activities indicate a mixed sentiment among investors, with a notable decrease in revenue and net profit year-on-year, suggesting potential challenges ahead for the company [1][2]. Group 1: Stock Performance and Financing - On November 11, NuoVaxan's stock rose by 0.17% with a trading volume of 36.08 million yuan [1]. - The financing buy-in amount for NuoVaxan on the same day was 3.48 million yuan, while the financing repayment was 4.09 million yuan, resulting in a net financing outflow of 610,400 yuan [1]. - As of November 11, the total financing and securities lending balance for NuoVaxan was 94.44 million yuan, with the financing balance at 93.64 million yuan, accounting for 0.99% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Company Overview and Financial Performance - NuoVaxan, established on March 16, 2012, and listed on November 15, 2021, specializes in the research and development of functional proteins and high molecular organic materials, with a focus on biological reagents and in vitro diagnostics [2]. - The company's revenue composition includes 81.86% from biological reagents, 9.99% from diagnostic reagents, 3.15% from consumables, 2.96% from equipment, 1.85% from technical services, and 0.18% from other sources [2]. - For the period from January to September 2025, NuoVaxan reported a revenue of 952 million yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2]. Group 3: Dividend Information - Since its A-share listing, NuoVaxan has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3].

南京诺唯赞生物科技股份有限公司 2025 年第一次临时股东会 会议资料 2025 年 11 月 南京诺唯赞生物科技股份有限公司 2025 年第一次临时股东会会议资料 南京诺唯赞生物科技股份有限公司 2025 年第一次临时股东会会议须知 为维护全体股东合法权益，确保股东会的正常秩序和议事效率，保证股东会 的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》、中国 证券监督管理委员会《上市公司股东会规则》以及《南京诺唯赞生物科技股份有 限公司章程》《南京诺唯赞生物科技股份有限公司股东大会议事规则》等有关规 定，南京诺唯赞生物科技股份有限公司（以下简称"公司"）特制定本次股东会 会议须知： 一、董事会在股东会召开过程中，应当以维护股东的合法权益、确保正常程 序和议事效率为原则，认真履行法定职责。股东会设立秘书处，负责会议有关程 序方面事宜。 二、各股东（含股东代理人，下同）请按照本次股东会会议通知中规定的时 间 和 登 记 方 法 办 理 参 会 手 续 ， 详 见 公 司 刊 登 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）的《关于召开 2025 年第一次临时股东会的通知》 ...

Market Overview - The Shanghai Composite Index closed at 4018.60 points, above the annual line, with a change of 0.53% [1] - The total trading volume of A-shares reached 2,194.371 billion yuan [1] Stocks Breaking Annual Line - A total of 112 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Shede Liquor: 9.90% - Binhai Energy: 8.36% - Pinwo Food: 6.38% [1] Detailed Stock Performance - The following table summarizes the performance of stocks that broke the annual line: - Shede Liquor (600702): Today's change of 10.01%, turnover rate of 7.58%, latest price 65.63 yuan [1] - Binhai Energy (000695): Today's change of 9.96%, turnover rate of 5.02%, latest price 12.47 yuan [1] - Pinwo Food (300892): Today's change of 8.84%, turnover rate of 16.98%, latest price 36.70 yuan [1] - Other notable stocks include: - Haida Co. (300320): 8.77% change, 9.19% turnover, latest price 10.91 yuan [1] - Huachao City A (000069): 9.92% change, 3.74% turnover, latest price 2.66 yuan [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that just crossed the annual line include: - Wanxin Media: Minor deviation rate [1] - Chengdu Bank: Minor deviation rate [1] - China Publishing: Minor deviation rate [1]

Market Overview - As of 10:30 AM today, the Shanghai Composite Index is at 3998.79 points, with a slight increase of 0.03% and total A-share trading volume reaching 1,083.642 billion yuan [1] Stocks Breaking Through Annual Line - A total of 76 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates including Binhai Energy at 8.36%, Overseas Chinese Town A at 6.04%, and Peking University Pharmaceutical at 5.58% [1] - The stocks with the largest deviation rates are as follows: - Binhai Energy: 9.96% increase, turnover rate of 4.54%, annual line at 11.51 yuan, latest price at 12.47 yuan [1] - Overseas Chinese Town A: 9.92% increase, turnover rate of 3.53%, annual line at 2.51 yuan, latest price at 2.66 yuan [1] - Peking University Pharmaceutical: 10.02% increase, turnover rate of 6.51%, annual line at 6.14 yuan, latest price at 6.48 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Shifeng Culture: 7.28% increase, turnover rate of 9.18%, annual line at 20.09 yuan, latest price at 20.92 yuan [1] - Shede Liquor: 3.72% increase, turnover rate of 2.05%, annual line at 59.70 yuan, latest price at 61.88 yuan [1] - Times Energy: 3.05% increase, turnover rate of 1.39%, annual line at 16.45 yuan, latest price at 16.92 yuan [1]

Group 1 - The core viewpoint of the news is that NuoVas has experienced fluctuations in its stock performance and financing activities, indicating a high level of trading activity and potential investor interest [1][2]. - On November 6, NuoVas' stock price decreased by 0.61%, with a trading volume of 32.48 million yuan. The financing buy-in amount was 2.79 million yuan, while the financing repayment was 2.27 million yuan, resulting in a net financing buy-in of 0.52 million yuan [1]. - As of November 6, the total balance of margin trading for NuoVas was 99.09 million yuan, with the financing balance accounting for 1.08% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - NuoVas, established on March 16, 2012, and listed on November 15, 2021, focuses on the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents, 9.99% from diagnostic reagents, and 3.15% from consumables [2]. - For the period from January to September 2025, NuoVas reported a revenue of 0.952 billion yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2]. - NuoVas has distributed a total of 0.731 billion yuan in dividends since its A-share listing, with 0.611 billion yuan distributed over the past three years [3].

Policy Developments - The National Medical Insurance Administration has initiated a pilot program for intelligent review of the entire process of medical insurance management, aiming to enhance the review capabilities and ensure the sustainable operation of medical insurance funds through the integration of AI technology [2]. Industry Developments - Chongqing has introduced measures to support high-quality development of innovative drugs, emphasizing the role of artificial intelligence in drug innovation and the establishment of a public service platform for "AI + pharmaceuticals" [3][4]. - Shanghai Pharmaceuticals has received FDA approval for its clopidogrel tablets, which are expected to generate approximately $1.284 billion in sales in the U.S. market in 2024, marking a significant opportunity for the company to expand its overseas market presence [6]. - NuoVation has obtained two medical device registration certificates for adenovirus antigen test kits, which are classified as Class III medical devices, indicating a step forward in the company's product offerings [7]. - Renfu Pharmaceutical has received approval for clinical trials of its HWH217 tablets, aimed at treating pulmonary arterial hypertension, with a total R&D investment of approximately 6 million yuan [8]. Capital Market - Pulsecare has successfully completed a financing round of over 100 million yuan, indicating strong investor interest in cardiovascular treatment technologies [10]. - Sunshine Nuohua has completed a share purchase plan by its associated company, acquiring 612,638 shares, which represents 0.55% of the total share capital, with an investment exceeding 28 million yuan [11]. Major Industry Events - The first batch of ovarian cancer treatment drugs has cleared customs in Beijing, marking a significant step in ensuring nationwide supply for this new treatment [13]. - Research from the Beijing Brain Science and Brain-like Research Institute has identified a new mechanism for treating depression, which could lead to the development of new antidepressant strategies with fewer side effects [14]. Regulatory Updates - Asia-Pacific Pharmaceutical has received a notification that its application for the consistency evaluation of diltiazem hydrochloride tablets has been rejected due to insufficient evidence supporting bioequivalence, indicating challenges in the drug development process [16].

Core Viewpoint - Novogene announced that its wholly-owned subsidiary, Nanjing Novogene Medical Technology Co., Ltd., has recently received two Medical Device Registration Certificates from the National Medical Products Administration [2] Group 1 - The company has achieved regulatory approval for its medical devices, which may enhance its market position and product offerings [2] - The issuance of these certificates indicates compliance with national standards, potentially leading to increased trust from healthcare providers and patients [2]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-048 南京诺唯赞生物科技股份有限公司 关于自愿披露全资子公司取得医疗器械 注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）全资子公司南京诺 唯赞医疗科技有限公司于近日收到国家药品监督管理局颁发的 2 项《医疗器械注 册证》，具体情况如下： 一、产品注册相关情况 （一）医疗器械注册证基本信息 | 序 | 名称 | 注册证编号 | | | | 注册分类 | 注册证 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | | | 有效期至 | | | | 1 | 腺病毒抗原检测试剂盒（胶体金法） | 国 | 械 | 注 | 准 | Ⅲ类 | 2030 年 | | | | | | 20253402230 | | | | | 11 月 3 | 日 | 体外定性检测人 | | 2 | 腺病毒抗 ...

Core Viewpoint - The company has received two medical device registration certificates from the National Medical Products Administration for its adenovirus antigen test kits, enhancing its competitive position in the respiratory pathogen detection market [1] Group 1: Product Development - The company’s subsidiary, Nanjing Novogene Medical Technology Co., Ltd., has developed two adenovirus antigen test kits: one using colloidal gold method and the other using quantum dot fluorescence immunochromatography method [1] - These test kits are designed for auxiliary diagnosis of respiratory adenovirus infections, which are particularly harmful to children under five years old [1] Group 2: Market Positioning - The approval of the adenovirus antigen test kits complements the company's existing rapid detection solutions for respiratory pathogens, catering to various clinical needs and application scenarios [1] - The company’s quantum dot platform, combined with already certified influenza A/B antigen and respiratory syncytial virus antigen tests, enables automated and high-sensitivity detection of five core respiratory pathogens [2] - The company’s product offerings meet the rapid testing needs of grassroots medical institutions, customs, and airports, enhancing its market reach [2]

Core Viewpoint - The approval of two medical device registration certificates for adenovirus antigen test kits enhances the company's respiratory pathogen rapid testing solutions, improving market competitiveness in the relevant field [1] Group 1: Product Development - The company’s subsidiary received two medical device registration certificates from the National Medical Products Administration for adenovirus antigen test kits using colloidal gold and quantum dot fluorescence immunochromatography methods [1] - The new adenovirus antigen test kits complement existing rapid testing solutions, catering to various application scenarios and clinical needs [1] Group 2: Technological Advancements - The quantum dot platform, combined with already certified influenza A/B antigen, respiratory syncytial virus antigen, and Mycoplasma pneumoniae antibody test kits, enables fully automated, high-sensitivity, quantitative detection of five core respiratory pathogens [1] - The automated fluorescence immunoassay system allows for sample input and result output, meeting the demand for large-scale automated testing in higher-level hospitals [1] Group 3: Market Applications - The colloidal gold platform for respiratory pathogen detection includes influenza A/B antigens, respiratory syncytial virus antigens, adenovirus antigens, and Mycoplasma pneumoniae antibody test kits, addressing rapid testing needs in primary healthcare institutions, customs, and airports [1]